

# EU biotechnology competitiveness for the future; high level dialogue with EVP Séjourné

## **PRESS RELEASE**

## Brussels, 10 April 2025

EuropaBio attended a high-level meeting to discuss the impact of the US tariffs with Executive Vice-President of the European Commission, Stéphane Séjourné and Director-General in charge of the Internal Market, Industry, Entrepreneurship and SMEs (DG GROW) Kerstin Jorna.

The meeting brought together CEOs and association representatives from across sectors in the two hour meeting. EuropaBio was represented through DG Claire Skentelbery and SwiftPharma CEO Jeroen Hofenk.

**Dr. Claire Skentelbery** commented "Today we could reinforce the significant asset that biotechnology is for industrial competitiveness across sectors for the EU. At the same time, supply chains are already disrupted and the EC must act in the short term to help companies continue to innovate to market, whilst also maximising the potential of the EU market for products from biotech and strengthening strategic global partnerships. EuropaBio was not alone in this call, and the EU holds its future in its own hands in delivering a single market that balances global trade, especially in times of instability."

#### **ENDS**

### **Media contact**

Email: communications@europabio.org

#### **About EuropaBio**

EuropaBio, the European Association for Bioindustries, promotes an innovative and dynamic European biotechnology industry. EuropaBio and its members are committed to the socially responsible use of biotechnology to improve quality of life; to prevent, diagnose, treat, and cure diseases; to improve the quality and quantity of food and feedstuffs and to move towards a biobased and zero-waste economy. EuropaBio represents corporate and associate members, plus national biotechnology associations and bioregions. Read more about our work at <a href="https://www.europabio.org">www.europabio.org</a>.

